Gaubert, Malo Lange, Catharina Garnier-Crussard, Antoine Köbe, Theresa Bougacha, Salma Gonneaud, Julie de Flores, Robin Tomadesso, Clémence Mézenge, Florence Landeau, Brigitte
...
Published in
Alzheimer's Research & Therapy
BackgroundWhite matter hyperintensities (WMH) are frequently found in Alzheimer’s disease (AD). Commonly considered as a marker of cerebrovascular disease, regional WMH may be related to pathological hallmarks of AD, including beta-amyloid (Aβ) plaques and neurodegeneration. The aim of this study was to examine the regional distribution of WMH asso...
Conti, Elisa Andreoni, Simona Tomaselli, Davide Storti, Benedetta Brovelli, Francesco Acampora, Roberto Da Re, Fulvio Appollonio, Ildebrando Ferrarese, Carlo Tremolizzo, Lucio
...
Published in
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Alzheimer's disease (AD) patients often express significant behavioral symptoms: for this reason, accessible related biomarkers could be very useful. Neuroinflammation is a key pathogenic process in both AD and delirium (DEL), a clinical condition with behavioral symptoms resembling those of AD. A total of n = 30 AD patients were recruited together...
Couly, Simon Denus, Morgane Bouchet, Mélanie Rubinstenn, Gilles Maurice, Tangui
Published in
The international journal of neuropsychopharmacology
Current therapies in Alzheimer's disease (AD), including Memantine, have proven to be only symptomatic but not curative or disease modifying. Fluoroethylnormemantine (FENM) is a structural analogue of Memantine, functionalized with a fluorine group that allowed its use as a positron emission tomography tracer. We here analyzed FENM neuroprotective ...
Lang, Merike Rosselli, Mónica Greig, Maria T Torres, Valeria L Vélez-Uribe, Idaly Arruda, Fernanda Barker, Warren W Garcia, Patricia Loewenstein, David A Curiel, Rosie E
...
Published in
Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists
To analyze (1) whether there are ethnic differences in the severity of depressive symptoms between groups of elders classified as cognitively normal (CN) or amnestic mild cognitive impairment (aMCI) and (2) the influence of depressive symptoms on specific cognitive performance by ethnicity across diagnoses, controlling for covariates. 164 Hispanics...
Ouk, Michael Wu, Che-Yuan Rabin, Jennifer S Jackson, Aaron Edwards, Jodi D Ramirez, Joel Masellis, Mario Swartz, Richard H Herrmann, Nathan Lanctôt, Krista L
...
Published in
Alzheimer's research & therapy
The antihypertensive angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) have similar indications and mechanisms of action, but prior work suggests divergence in their effects on cognition. Participants in the National Alzheimer's Coordinating Center database with a clinical diagnosis of dementia due to Alzhei...
Ou, Ya-Nan Yang, Yu-Xiang Shen, Xue-Ning Ma, Ya-Hui Chen, Shi-Dong Dong, Qiang Tan, Lan Yu, Jin-Tai
Published in
Alzheimer's Research & Therapy
BackgroundObservational studies suggest that the use of antihypertensive medications (AHMs) is associated with a reduced risk of Alzheimer’s disease (AD); however, these findings may be biased by confounding and reverse causality. We aimed to explore the effects of blood pressure (BP) and lowering systolic BP (SBP) via the protein targets of differ...
Jiménez-Balado, Joan Eich, Teal S
Published in
Seminars in cell & developmental biology
In this review, we focus on the potential role of the γ-aminobutyric acidergic (GABAergic) system in age-related episodic memory impairments in humans, with a particular focus on Alzheimer's disease (AD). Well-established animal models have shown that GABA plays a central role in regulating and synchronizing neuronal signaling in the hippocampus, a...
Cicognola, Claudia Hansson, Oskar Scheltens, Philip Kvartsberg, Hlin Zetterberg, Henrik Teunissen, Charlotte E. Blennow, Kaj
Published in
Alzheimer's Research & Therapy
BackgroundElevated cerebrospinal fluid (CSF) concentrations of total tau (T-tau) and phosphorylated tau at Thr181 (P-tau181) protein are typical of Alzheimer’s disease (AD). However, the T-tau assay measures only the mid-region of the protein, while tau in CSF is instead composed of a series of fragments. One fragment species in particular, N-224, ...
Tsoy, Elena Strom, Amelia Iaccarino, Leonardo Erlhoff, Sabrina J. Goode, Collette A. Rodriguez, Anne-Marie Rabinovici, Gil D. Miller, Bruce L. Kramer, Joel H. Rankin, Katherine P.
...
Published in
Alzheimer's Research & Therapy
Backgroundβ-amyloid (Aβ) and tau positron emission tomography (PET) detect the pathological changes that define Alzheimer’s disease (AD) in living people. Cognitive measures sensitive to Aβ and tau burden may help streamline identification of cases for confirmatory AD biomarker testing.MethodsWe examined the association of Brain Health Assessment (...
Maiti, Panchanan Bowers, Zackary Bourcier-Schultz, Ali Morse, Jarod Dunbar, Gary L.
Published in
Alzheimer's Research & Therapy
BackgroundSynaptic failure is one of the principal events associated with cognitive dysfunction in Alzheimer’s disease (AD). Preservation of existing synapses and prevention of synaptic loss are promising strategies to preserve cognitive function in AD patients. As a potent natural anti-oxidant, anti-amyloid, and anti-inflammatory polyphenol, curcu...
